BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. In animal models it consistently accelerates healing of tendons, ligaments, muscle, and gut tissue — proposed mechanisms include upregulation of growth factor receptors (VEGFR2, FGFR2) and modulation of nitric oxide signaling. The GI preclinical evidence is particularly consistent, with rodent studies showing protection against NSAID-induced ulcers, colitis, and gut permeability disruptions. No peer-reviewed human randomized controlled trials have been completed, so extrapolating the animal data to clinical outcomes involves significant uncertainty, and it remains an unregulated research compound.
Evidence last reviewed: 04 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Verify this peptide on CertiPep
certipep.ch — anonymous purity & characterization service
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
Preclinical studies indicate BPC-157 may enhance healing in various tissues, but the evidence is limited to animal models. The absence of peer-reviewed human trials creates significant uncertainty regarding its clinical application.
Safety / pharmacokineticsHealthy volunteers · Registered phase 1 trial (results not posted)Low
A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.
Soft tissue healing signals (preclinical)Animal models (multiple tissues) · Review (preclinical-focused)Low
Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.
Musculoskeletal healing (preclinical)Animal injury models (multiple tissues) · Narrative review of preclinical evidenceLow
Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.
Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).
Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.
Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.
BPC-157 & TB-500 are the two most researched recovery peptides, with complementary mechanisms. BPC-157 (Body Protection Compound) accelerates tendon, ligament, & gut repair via angiogenesis & growth factor upregulation. TB-500 (Thymosin Beta-4) promotes systemic tissue repair, reduces inflammation, & improves mobility. GHK-Cu supports collagen synthesis & skin regeneration. Note: all three are research compounds not approved for human therapeutic use.
KLOW Stack
The KLOW stack is a 4-peptide protocol targeting systemic inflammation, tissue repair, and cellular regeneration. It combines BPC-157 (gut and musculoskeletal healing), TB-500 (vascularisation and muscle/tendon recovery), KPV (anti-inflammatory gut protection), and GHK-Cu (collagen remodelling and skin/hair health). It is designed as an evolution of the GLOW stack with a stronger anti-inflammatory focus and broader systemic repair coverage.